4:41 PM · 7 June 2021

Biogen trading paused after company received approval for its Alzheimer's drug

Biogen
Stocks
BIIB.US, Biogen Inc
-
-

Biogen (BIIB.US) stock has been halted  after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.

Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5

13 October 2025, 5:05 PM

Goldman Sachs boosts sentiment on Estée Lauder shares 💡

13 October 2025, 3:28 PM

US OPEN: "Green" Start to the Week on Wall Street

13 October 2025, 2:37 PM

OpenAI Announces Partnership with Broadcom. Company Shares Soar!

13 October 2025, 12:16 PM

DE40: Europe's markets recovering from correction

Join over 1 700 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits